Profluent Bio

Profluent is a protein design company that uses AI to author new proteins rather than relying on random discovery. Its platform combines frontier foundation models with an in house wet lab, so that each design step can be aligned to a target use case. The company's published work includes language models that generate functional protein sequences across diverse families and models of CRISPR Cas sequences used to design genome editors. The company works with partners across therapeutics, agriculture and industrial enzymes. Its capabilities include optimizing multiple protein attributes at once, reaching sequence diversity beyond natural or patented proteins, and enabling functions that nature does not provide. Its first focus is CRISPR and gene editing, where it releases OpenCRISPR, which the vendor presents as an AI designed gene editor. The news section records partnerships with Eli Lilly and BioMarin to design medicines using AI. Profluent is a development partner rather than a self service software product. The site has a platform page with a technical overview, key publications, a team page and a partnerships page, but no signup, trial or public plans. The vendor does not publish pricing, and commercial terms are agreed through partnership agreements.